|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Brucellosis in Turkey — an overview显示文摘 | Zeki Yumuk David O’Callaghan | 2012 | International Journal of Infectious Diseases2012，，： | 1 |
| 2 | Brucellosis: a worldwide zoonosis显示文摘 | Maria-Laura Boschiroli Vincent Foulongne David O’Callaghan | 2001 | Current Opinion in Microbiology2001，，1： | 1 |
| 3 | Brucellosis in China:history,progress and challenge显示文摘Brucellosis is a neglected zoonosis.It causes acute febrile illness and a potentially debilitating chronic infection in humans,and livestock infection has substantial socioeconomic impact.Over the past two decades,improvements have been made to better understand the various aspects of human and animal brucellosis.Meanwhile,especially in the developing world,immense challenges that remain in controlling and eradicating brucellosis are novel diagnostics tools and efficacious vaccines.Here,we will focus on the remarkable issues on epidemiological survey,as well as the priority and challenge of brucellosis in China.Brucellosis will be controlled with meaningful collaboration between local and public partnerships effectively applying a One Health framework. | Hai Jiang David O’Callaghan Jia-Bo Ding | 2020 | Infectious Diseases of Poverty2020，9，3： | 25 |
| 4 | Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial显示文摘 | Phil Quirke Robert Steele John Monson Robert Grieve Subhash Khanna Jean Couture Chris O’Callaghan Arthur Sun Myint Eric Bessell Lindsay C Thompson Mahesh Parmar Richard J Stephens David Sebag-Montefiore | 2009 | The Lancet2009，，9666： | 1 |
| 5 | Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial显示文摘 | Phil Quirke Robert Steele John Monson Robert Grieve Subhash Khanna Jean Couture Chris O’Callaghan Arthur Sun Myint Eric Bessell Lindsay C Thompson Mahesh Parmar Richard J Stephens David Sebag-Montefiore | 2009 | The Lancet . 2009 (9666)2009，，9666： | 1 |
| 6 | Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings显示文摘Object:To determine the extent and impact of upgrading and downgrading among men who underwent radical prostatectomy(RP)according to new grade groupings and to identify predictors of upgrading from biopsy grade Group Ⅰ and Ⅱ,and downgrading to grade Group I,in a community setting.Methods:Study participants included 2279 men with non-metastatic prostate cancer diagnosed 2006-2015 who underwent prostatectomy,from the multi-institutional South Australia Prostate Cancer Clinical Outcomes Collaborative registry.Extent of up-or down-grading was assessed by comparing biopsy and prostatectomy grade groupings.Risk of biochemical recurrence(BCR)with upgrading was assessed using multivariable competing risk regression.Binomial logistic regression was used to identify pre-treatment predictors of upgrading from grade Groups Ⅰ and Ⅱ,and risk group reclassification among men with low risk disease.Results:Upgrading occurred in 35%of cases,while downgrading occurred in 13%of cases.Sixty percent with grade Group I disease were upgraded following prostatectomy.Upgrading from grade Group I was associated with greater risk of BCR compared with concordant grading(Hazard ratio:3.1,95%confidence interval:1.7-6.0).Older age,higher prostate-specific antigen levels(PSA),fewer biopsy cores,higher number of positive cores and more recent diagnosis predicted upgrading from grade Group Ⅰ,while higher PSA and clinical stage predicted upgrading from grade Group Ⅱ.No clinical risk factors for reclassification were identified.Conclusion:Biopsy sampling errors may play an important role in upgrading from grade Group I.Improved clinical assessment of grade is needed to encourage greater uptake of active surveillance. | Kerri Beckmann Michael O’Callaghan Andrew Vincent Penelope Cohen Martin Borg David Roder Sue Evans Jeremy Millar Kim Moretti | 2019 | Asian Journal of Urology2019，6，4： | 1 |
| 7 | Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study显示文摘 | Glenwood D. Goss Chris O’Callaghan Ian Lorimer Ming-Sound Tsao Gregory A. Masters James Jett Martin J. Edelman Rogerio Lilenbaum Hak Choy Fadlo Khuri Katherine Pisters David Gandara Kemp Kernstine Charles Butts Jonathan Noble Thomas A. Hensing Kendrith Ro | 2013 | Journal of Clinical Oncology2013，，27： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员